Elanco Animal Health Incorporated (NYSE:ELAN) Stock Position Raised by Boothbay Fund Management LLC

Boothbay Fund Management LLC increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 11.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,055,567 shares of the company’s stock after acquiring an additional 203,467 shares during the quarter. Elanco Animal Health makes up 0.6% of Boothbay Fund Management LLC’s holdings, making the stock its 16th largest holding. Boothbay Fund Management LLC owned about 0.42% of Elanco Animal Health worth $24,893,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Steward Partners Investment Advisory LLC increased its stake in Elanco Animal Health by 28.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock worth $124,000 after purchasing an additional 2,264 shares in the last quarter. DDD Partners LLC purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $5,974,000. Harbor Capital Advisors Inc. boosted its stake in Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after purchasing an additional 209,734 shares during the period. Franklin Resources Inc. grew its position in Elanco Animal Health by 14.0% during the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock worth $5,349,000 after purchasing an additional 45,795 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its stake in Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after purchasing an additional 2,059 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were bought at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now directly owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.89% of the company’s stock.

Elanco Animal Health Trading Down 0.1 %

Shares of NYSE:ELAN opened at $9.45 on Friday. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $4.69 billion, a PE ratio of 23.63, a P/E/G ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.80. The firm has a fifty day moving average price of $10.03 and a 200 day moving average price of $11.66.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter last year, the company posted $0.08 EPS. The business’s revenue was down 1.4% compared to the same quarter last year. Analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ELAN. Barclays lowered their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Morgan Stanley lowered their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. UBS Group cut their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Finally, Stifel Nicolaus cut their price objective on Elanco Animal Health from $15.00 to $13.00 and set a “buy” rating for the company in a report on Monday, April 14th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Hold” and an average price target of $14.67.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.